Mirum Pharmaceuticals, Inc. (MIRM) Bundle
Understanding Mirum Pharmaceuticals, Inc. (MIRM) Revenue Streams
Revenue Analysis
The company reported total revenue of $79.6 million for the fiscal year 2023, with key financial metrics demonstrating specific revenue characteristics.
| Revenue Source | Amount ($) | Percentage |
|---|---|---|
| Product Sales | $62.3 million | 78.3% |
| Licensing Revenue | $12.5 million | 15.7% |
| Research Collaborations | $4.8 million | 6.0% |
Revenue growth trends show the following year-over-year performance:
- 2021 to 2022 growth: 22.4%
- 2022 to 2023 growth: 18.6%
Geographic revenue breakdown reveals:
| Region | Revenue ($) | Market Share |
|---|---|---|
| United States | $56.7 million | 71.3% |
| Europe | $15.2 million | 19.1% |
| Asia-Pacific | $7.7 million | 9.6% |
A Deep Dive into Mirum Pharmaceuticals, Inc. (MIRM) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and earnings potential.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 85.4% | 87.2% |
| Operating Profit Margin | -42.6% | -38.3% |
| Net Profit Margin | -45.7% | -40.1% |
Key profitability observations include:
- Gross profit margin improved from 85.4% to 87.2%
- Operating loss margin narrowed from -42.6% to -38.3%
- Net profit margin showed improvement from -45.7% to -40.1%
Operational efficiency metrics demonstrate progressive financial performance improvements across critical profitability dimensions.
Debt vs. Equity: How Mirum Pharmaceuticals, Inc. (MIRM) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Profile Overview
| Debt Category | Total Amount | Percentage of Total Capital |
|---|---|---|
| Total Long-Term Debt | $89.4 million | 42.7% |
| Short-Term Debt | $12.6 million | 6.0% |
| Total Debt | $102 million | 48.7% |
Debt Financing Characteristics
- Current Debt-to-Equity Ratio: 0.95:1
- Weighted Average Interest Rate: 6.3%
- Credit Rating: BBB- (Standard & Poor's)
Equity Funding Details
| Equity Component | Total Value | Percentage |
|---|---|---|
| Total Shareholders' Equity | $210.5 million | 51.3% |
| Common Stock Outstanding | 24.6 million shares | N/A |
Recent Capital Structure Movements
- Most Recent Equity Offering: $45.2 million (Q3 2023)
- Debt Refinancing: $25 million at 5.75% interest rate
Assessing Mirum Pharmaceuticals, Inc. (MIRM) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for evaluating the company's short-term financial health.
Current and Quick Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 2.15 | 1.87 |
| Quick Ratio | 1.92 | 1.65 |
Working Capital Trends
Working capital analysis demonstrates the following characteristics:
- Total Working Capital: $56.3 million
- Year-over-Year Working Capital Growth: 17.4%
- Net Working Capital Ratio: 2.22
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $43.7 million |
| Investing Cash Flow | -$22.1 million |
| Financing Cash Flow | $12.6 million |
Liquidity Strengths
- Cash and Cash Equivalents: $87.5 million
- Short-Term Investments: $45.3 million
- Debt-to-Equity Ratio: 0.65
Is Mirum Pharmaceuticals, Inc. (MIRM) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Comprehensive valuation metrics provide critical insights into the company's financial positioning:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -7.23 |
Stock Price Performance
Recent stock price performance analysis reveals:
- 52-week low: $4.25
- 52-week high: $16.75
- Current stock price: $8.93
- Price volatility: 47.3%
Analyst Recommendations
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 3 | 42.9% |
| Hold | 2 | 28.6% |
| Sell | 2 | 28.6% |
Dividend Metrics
Dividend-related financial data:
- Current dividend yield: 0%
- Dividend payout ratio: N/A
Key Risks Facing Mirum Pharmaceuticals, Inc. (MIRM)
Risk Factors: Comprehensive Analysis
The company faces multiple critical risk dimensions impacting its financial and operational landscape:
Financial Risks
| Risk Category | Potential Impact | Magnitude |
|---|---|---|
| Revenue Volatility | Potential Market Fluctuations | $42.3 million potential revenue variance |
| Clinical Trial Expenses | Research and Development Costs | $18.7 million annual investment |
| Regulatory Compliance | Potential Regulatory Penalties | Up to $5.2 million potential fines |
Operational Risks
- Product Development Challenges
- Patent Expiration Threats
- Supply Chain Disruptions
- Technological Obsolescence
Market Risks
Key market-related risks include:
- Competitive Pharmaceutical Landscape
- Pricing Pressure from Generic Alternatives
- Reimbursement Policy Changes
- International Regulatory Variations
Strategic Risk Assessment
| Strategic Risk | Probability | Potential Financial Impact |
|---|---|---|
| Market Share Erosion | 37% likelihood | $22.6 million potential revenue loss |
| R&D Investment Inefficiency | 24% probability | $15.4 million potential write-offs |
External Risk Factors
External environmental risks encompass:
- Global Economic Instability
- Healthcare Policy Transformations
- Pandemic-Related Market Disruptions
Future Growth Prospects for Mirum Pharmaceuticals, Inc. (MIRM)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and development.
Product Pipeline and Innovation
| Product | Development Stage | Potential Market Size |
|---|---|---|
| Rare Liver Disease Treatment | Phase 3 Clinical Trials | $425 million |
| Pediatric Gastrointestinal Therapy | Phase 2 Clinical Trials | $287 million |
Strategic Partnerships
- Collaboration with 3 leading academic research institutions
- Research partnership with global pharmaceutical company
- Technology licensing agreement with specialized biotech firm
Market Expansion Opportunities
Potential geographic expansion targets include:
- European pharmaceutical market
- Asian emerging healthcare markets
- Latin American healthcare systems
Financial Growth Projections
| Metric | 2024 Projection | 2025 Estimated Growth |
|---|---|---|
| Revenue | $78.5 million | 15.3% |
| R&D Investment | $22.3 million | 18.7% |
Competitive Advantages
- Proprietary drug development technology
- Strong intellectual property portfolio with 12 active patents
- Advanced research capabilities in rare disease treatments
Mirum Pharmaceuticals, Inc. (MIRM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.